Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer’s Disease

2015 ◽  
Vol 48 (3) ◽  
pp. 637-646 ◽  
Author(s):  
Daniel Åberg ◽  
Per Johansson ◽  
Jörgen Isgaard ◽  
Anders Wallin ◽  
Jan-Ove Johansson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level ◽  
Factor Ii ◽  
Male Patients

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease

2013 ◽  
Vol 38 (7) ◽  
pp. 1058-1066 ◽  
Author(s):  
Per Johansson ◽  
Erik G. Almqvist ◽  
Jan-Ove Johansson ◽  
Niklas Mattsson ◽  
Oskar Hansson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level

Patients with Alzheimer’s Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid

2020 ◽  
Vol 75 (1) ◽  
pp. 289-298 ◽  
Author(s):  
Alexandra Horvath ◽  
Zeinab Salman ◽  
Patrick Quinlan ◽  
Anders Wallin ◽  
Johan Svensson
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Growth Factor I

Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease

2014 ◽  
Vol 42 (3) ◽  
pp. 901-908 ◽  
Author(s):  
Anna Antonell ◽  
Alicia Mansilla ◽  
Lorena Rami ◽  
Albert Lladó ◽  
Alex Iranzo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level ◽  
Prodromal Alzheimer’S Disease

Decreased Levels of Insulin-Like Growth Factor-1 Are Associated with Alzheimer’s Disease: A Meta-Analysis

2021 ◽  
pp. 1-11
Author(s):  
Ling-Zhi Xu ◽  
Fang-Yu Li ◽  
Bing-Qiu Li ◽  
Shu-Man Cao ◽  
Yan Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Growth Factor ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Age Difference ◽  
Insulin Like Growth Factor ◽  
Significant Difference ◽  
Healthy Control

Background: Alterations in levels of peripheral insulin-like growth factor-1 (IGF-1) in Alzheimer’s disease (AD) have been reported in several studies, and results are inconsistent. Objective: We conducted a meta-analysis to investigate the relationship between peripheral and cerebrospinal fluid IGF-1 levels and AD or mild cognitive impairment (MCI). Methods: A systematic search in PubMed, Medline, Web of Science, Embase, and Cochrane Library was conducted and 18 studies were included. Results: Results of random-effects meta-analysis showed that there was no significant difference between AD patients and healthy control (17 studies; standard mean difference [SMD], –0.01; 95%CI, –0.35 to 0.32) and between MCI patients and healthy control (6 studies; SMD, –0.20; 95%CI, –0.52 to 0.13) in peripheral IGF-1 levels. Meta-regression analyses identified age difference might explain the heterogeneity (p = 0.017). However, peripheral IGF-1 levels were significantly decreased in AD subjects (9 studies; SMD, –0.44; 95%CI, –0.81 to –0.07) and MCI subjects exhibited a decreasing trend (4 studies; SMD, –0.31; 95%CI, –0.72 to 0.11) in studies with sample size≥80. Cerebrospinal fluid IGF-1 levels also significantly decreased in AD subjects (3 studies; SMD, –2.40; 95%CI, –4.36 to –0.43). Conclusion: These findings suggest that decreased peripheral and cerebrospinal fluid IGF-1 levels might be a potential marker for the cognitive decline and progression of AD.

scholarly journals Increased Circulating Insulin-like Growth Factor-1 in Late-onset Alzheimer's Disease

2007 ◽  
Vol 12 (4) ◽  
pp. 285-290 ◽  
Author(s):  
Emma R.L.C. Vardy ◽  
Penny J. Rice ◽  
Peter C.W. Bowie ◽  
John D. Holmes ◽  
Peter J. Grant ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Growth Factor ◽  
Late Onset ◽  
Insulin Like Growth Factor
Sign in / Sign up

Export Citation Format

Share Document